Key Events This Week
Mar 09: Intraday high surge to Rs.1,537 (+7.79%)
Mar 11: MarketsMOJO upgrades rating to Buy
Mar 13: Technical momentum shifts to mildly bullish
Mar 13: Week closes at Rs.1,437.20 (+1.58% weekly)

Emcure Pharmaceuticals Ltd: Technical Momentum Shifts Signal Mildly Bullish Outlook
2026-03-13 08:02:59Emcure Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish trend as of early March 2026. Despite a recent day decline of 3.07%, the stock’s underlying technical indicators present a nuanced picture, reflecting both cautious optimism and emerging bearish signals. This analysis delves into the key technical parameters shaping Emcure’s near-term outlook, alongside its comparative market performance.
Read full news article
Emcure Pharmaceuticals Upgraded to Buy on Strong Financials and Market Outperformance
2026-03-12 08:16:44Emcure Pharmaceuticals Ltd has been upgraded from a Hold to a Buy rating by MarketsMOJO as of 11 March 2026, reflecting a marked improvement across key investment parameters including quality, valuation, financial trends, and technical indicators. This upgrade follows a series of robust quarterly performances and growing institutional interest, positioning the company favourably within the Pharmaceuticals & Biotechnology sector.
Read full news article
Emcure Pharmaceuticals Ltd Hits Intraday High with 7.79% Surge on 9 March 2026
2026-03-09 14:04:54Emcure Pharmaceuticals Ltd demonstrated a robust intraday performance on 9 Mar 2026, surging to an intraday high of Rs 1,537, marking an 8.64% increase from its previous close. The stock closed with a notable gain of 7.79%, significantly outperforming its sector and broader market indices amid a generally negative market environment.
Read full news article
Emcure Pharmaceuticals Ltd is Rated Hold
2026-03-02 10:10:36Emcure Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 18 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 02 March 2026, providing investors with the most up-to-date insight into the stock’s fundamentals, returns, and overall outlook.
Read full news articleEmcure Pharmaceuticals Declines 3.37%: Mixed Technical Signals and Valuation Concerns Shape the Week
2026-02-21 09:01:16
Key Events This Week
16 Feb: Emcure upgraded to Buy on strong financials and bullish technicals
17 Feb: Technical momentum shifts amid mixed market signals
18 Feb: Downgrade to Hold reflecting mixed technical and valuation signals
20 Feb: Week closes at ₹1,438.55 (-3.37%) versus Sensex +0.39%
Clarification On Volume Movement Letter
10-Mar-2026 | Source : BSEClarification on Volume Movement Letter
Clarification sought from Emcure Pharmaceuticals Ltd
10-Mar-2026 | Source : BSEThe Exchange has sought clarification from Emcure Pharmaceuticals Ltd on March 10 2026 with reference to Movement in Volume.
The reply is awaited.
Announcement under Regulation 30 (LODR)-Change in Management
09-Mar-2026 | Source : BSEAppointment of Independent Director of the Company.
Corporate Actions
No Upcoming Board Meetings
Emcure Pharmaceuticals Ltd has declared 30% dividend, ex-date: 14 Aug 25
No Splits history available
No Bonus history available
No Rights history available









